{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:49:34Z","timestamp":1787759374630,"version":"build-2784847793"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Paratek Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The pharmacodynamics of omadacycline have been extensively studied against Gram-positive pathogens but less information is available for Gram-negative pathogens. We describe the pre-clinical pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An in vitro dilutional pharmacokinetic model was used. Exposure experiments with fAUC\/MIC ratios ranging from 0 to 1200 were performed using five strains of E. coli and five strains of A. baumannii. Reduction in bacterial load and changes in population profiles were measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The fAUC\/MIC targets against E. coli for 24\u2009h static and \u22121\u2009log reduction in load were 25.3\u200a\u00b1\u200a17.2 and 42.7\u200a\u00b1\u200a32.5, respectively. For A. baumannii the fAUC\/MIC for 24\u2009h static effect was 108.1\u200a\u00b1\u200a38.6. Changes in population profiles were observed for E. coli at fAUC\/MIC ratios of \u2264200 and for A. baumannii up to 1200. MICs were increased 2\u201332 fold.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>fAUC\/MIC targets for A. baumannii are greater than for E.coli and changes in population profiles more likely. E. coli fAUC\/MIC targets align with in vivo data and will be useful in determining omadacycline dosing for this pathogen.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa508","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T13:32:43Z","timestamp":1605706363000},"page":"667-670","source":"Crossref","is-referenced-by-count":22,"title":["<i>In vitro<\/i> pharmacodynamics of omadacycline against <i>Escherichia coli<\/i> and <i>Acinetobacter baumannii<\/i>"],"prefix":"10.1093","volume":"76","author":[{"given":"A R","family":"Noel","sequence":"first","affiliation":[{"name":"Bristol Centre for Antimicrobial Research and Evaluation (BCARE), Infection Sciences, Severn Pathology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Attwood","sequence":"additional","affiliation":[{"name":"Bristol Centre for Antimicrobial Research and Evaluation (BCARE), Infection Sciences, Severn Pathology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K E","family":"Bowker","sequence":"additional","affiliation":[{"name":"Bristol Centre for Antimicrobial Research and Evaluation (BCARE), Infection Sciences, Severn Pathology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A P","family":"MacGowan","sequence":"additional","affiliation":[{"name":"Bristol Centre for Antimicrobial Research and Evaluation (BCARE), Infection Sciences, Severn Pathology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"2021021208585029600_dkaa508-B1","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/cid\/ciz309","article-title":"Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline","volume":"69","author":"Rodvold","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021021208585029600_dkaa508-B2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2021021208585029600_dkaa508-B3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/AAC.44.4.943-949.2000","article-title":"In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152\u200a288) against various Gram-positive and Gram-negative bacteria","volume":"44","author":"van Ogtrop","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208585029600_dkaa508-B4","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1128\/AAC.00922-07","article-title":"Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model","volume":"52","author":"Bowker","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208585029600_dkaa508-B5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the treatment of multidrug and extensively drug resistant A. baumannii: a review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2021021208585029600_dkaa508-B6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12941-017-0199-8","article-title":"The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2021021208585029600_dkaa508-B7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/14787210.2019.1681975","article-title":"Eravacycline for the treatment of complicated intra-abdominal infections","volume":"17","author":"Montravers","year":"2019","journal-title":"Expert Rev anti Infect Ther"},{"key":"2021021208585029600_dkaa508-B8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.47.3.1088-1095.2003","article-title":"Activities of moxifloxacin against, and emergence of resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model","volume":"47","author":"MacGowan","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208585029600_dkaa508-B9","year":"2019"},{"key":"2021021208585029600_dkaa508-B10","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/AAC.01678-08","article-title":"In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates","volume":"53","author":"Nicasio","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208585029600_dkaa508-B11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jac\/dkp254","article-title":"Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended spectrum \u03b2-lactamases, AmpC \u03b2-lactamases and reduced susceptibility to carbapenems using an in vitro model","volume":"64","author":"Zhanel","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2021021208585029600_dkaa508-B12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/AAC.00813-07","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections","volume":"52","author":"Passarell","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208585029600_dkaa508-B13","doi-asserted-by":"crossref","first-page":"e00250-17","DOI":"10.1128\/AAC.00250-17","article-title":"In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208585029600_dkaa508-B14","doi-asserted-by":"crossref","first-page":"e00624-19","DOI":"10.1128\/AAC.00624-19","article-title":"In vivo pharmacodynamics of omadacycline against Staphylococcus aureus in the neutropenic murine thigh infection model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208585029600_dkaa508-B15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jac\/dkp056","article-title":"Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model","volume":"63","author":"Koomanachai","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2021021208585029600_dkaa508-B16","doi-asserted-by":"crossref","first-page":"e01671-18","DOI":"10.1128\/AAC.01671-18","article-title":"Pharmacodynamics of minocycline against Acinetobacter baumannii in a rat pneumonia model","volume":"63","author":"Tarazi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021021208585029600_dkaa508-B17","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/cid\/ciz395","article-title":"Microbiology and preclinical review of omadacycline","volume":"69","author":"Karlowsky","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021021208585029600_dkaa508-B18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ijantimicag.2017.06.026","article-title":"Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection","volume":"50","author":"Alfouzan","year":"2017","journal-title":"J Antimicrob Agents"},{"key":"2021021208585029600_dkaa508-B19","doi-asserted-by":"crossref","first-page":"e02327-17","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY Antimicrobial Surveillance Program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/667\/36240988\/dkaa508.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/3\/667\/36240988\/dkaa508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:26:53Z","timestamp":1613176013000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/3\/667\/6028469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,9]]},"published-print":{"date-parts":[[2021,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa508","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,12,9]]}}}